Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2015	Oct. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Trading Symbol	RKDA
Entity Registrant Name	ARCADIA BIOSCIENCES, INC.
Entity Central Index Key	0001469443
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		44,083,195

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 62,966,000	$ 16,571,000
Short-term investments	11,290,000
Accounts receivable	685,000	1,042,000
Unbilled revenue	431,000	380,000
Inventories — current	598,000	424,000
Prepaid expenses and other current assets	672,000	278,000
Total current assets	76,642,000	18,695,000
Property and equipment, net	597,000	728,000
Inventories — noncurrent	2,132,000	2,149,000
Cost method investment	500,000	500,000
Other noncurrent assets	102,000	2,817,000
Total assets	79,973,000	24,889,000
Current liabilities:
Accounts payable and accrued expenses	3,976,000	3,197,000
Amounts due to related parties	15,000	56,000
Promissory notes — current		1,055,000
Convertible promissory notes	3,639,000	4,551,000
Unearned revenue — current	840,000	830,000
Derivative liabilities related to convertible promissory notes	2,425,000	1,580,000
Total current liabilities	10,895,000	11,269,000
Notes payable	19,462,000
Note payable to related party		8,000,000
Promissory notes — noncurrent		869,000
Unearned revenue — noncurrent	2,783,000	3,636,000
Other noncurrent liabilities	3,000,000	3,000,000
Total liabilities	36,140,000	26,774,000
Stockholders’ equity (deficit):
Preferred stock, $0.001 par value—20,000,000 and 0 shares authorized as of September 30, 2015 and December 31, 2014; no shares issued and outstanding as of September 30, 2015 and December 31, 2014
Common stock, $0.001 par value—400,000,000 and 140,000,000 shares authorized as of September 30, 2015 and December 31, 2014; 43,931,094 and 2,074,030 shares issued and outstanding as of September 30, 2015 and December 31, 2014	44,000
Additional paid-in capital	171,858,000	29,204,000
Accumulated deficit	(128,069,000)	(113,970,000)
Total stockholders’ equity (deficit)	43,833,000	(84,766,000)
Total liabilities, redeemable and convertible preferred stock and stockholders’ equity (deficit)	79,973,000	24,889,000
Redeemable Convertible Preferred Stock [Member]
Current liabilities:
Convertible preferred stock		34,098,000
Convertible Preferred Stock [Member]
Current liabilities:
Convertible preferred stock		$ 48,783,000

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) (USD $)	Sep. 30, 2015	Dec. 31, 2014
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, authorized	20,000,000	0
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	400,000,000	140,000,000
Common stock, issued	43,931,094	2,074,030
Common stock, outstanding	43,931,094	2,074,030
Redeemable Convertible Preferred Stock [Member]
Convertible preferred stock, no par value	$ 0	$ 0
Convertible preferred stock, authorized	0	10,553,770
Convertible preferred stock, issued	0	9,587,764
Convertible preferred stock, outstanding	0	9,587,764
Convertible Preferred Stock [Member]
Convertible preferred stock, no par value	$ 0	$ 0
Convertible preferred stock, authorized	0	94,586,346
Convertible preferred stock, issued	0	23,385,029
Convertible preferred stock, outstanding	0	23,385,029

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenues:
Product	$ 123	$ 67	$ 383	$ 266
License	214	91	773	462
Contract research and government grants	1,486	1,344	2,912	3,456
Total revenues (which includes $23, $23, $68 and $68 from related parties — Note 8)	1,823	1,502	4,068	4,184
Operating expenses:
Cost of product revenues	61	1,795	223	1,932
Research and development	3,179	3,684	7,097	7,942
Selling, general and administrative	2,818	1,966	8,241	7,833
Total operating expenses	6,058	7,445	15,561	17,707
Loss from operations	(4,235)	(5,943)	(11,493)	(13,523)
Interest expense	(766)	(265)	(2,008)	(1,048)
Other income (expense), net	285	(813)	(376)	(613)
Net loss before income taxes and equity in loss of unconsolidated entity	(4,716)	(7,021)	(13,877)	(15,184)
Income tax benefit (provision)	97	(43)	(222)	(235)
Equity in loss of unconsolidated entity				(932)
Net loss and comprehensive loss	(4,619)	(7,064)	(14,099)	(16,351)
Accretion of redeemable convertible preferred stock to redemption value		(1,570)	(2,574)	(2,088)
Deemed dividends to warrant holder			(197)
Net loss attributable to common stockholders	$ (4,619)	$ (8,634)	$ (16,870)	$ (18,439)
Net loss per share attributable to common stockholders:
Basic and diluted	$ (0.11)	$ (4.19)	$ (0.72)	$ (8.96)
Weighted-average number of shares used in per share calculations:
Basic and diluted	43,647,180	2,061,805	23,318,262	2,058,327

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Revenues from related parties	$ 23	$ 23	$ 68	$ 68

Condensed Consolidated Statements of Redeemable and Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) (USD $) In Thousands, except Share data	Total USD ($)	Preferred Stock [Member]	Common Stock [Member] USD ($)	Additional Paid-In Capital [Member] USD ($)	Accumulated Deficit [Member] USD ($)	Redeemable Convertible Preferred Stock [Member] USD ($)	Convertible Preferred Stock [Member] USD ($)
Stockholders Equity, Beginning Balance at Dec. 31, 2013	$ (17,297)			$ 78,334	$ (95,631)
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2013		23,385,029	2,056,557
Exercise of stock options	19			19
Exercise of stock options, Shares			17,473
Preferred stock reclassification	(48,783)			(48,783)			48,783
Preferred stock reclassification, Shares		(23,385,029)					23,385,029
Stock-based compensation	976			976
Issuance of preferred stock, net of issuance cost of $194						30,360
Issuance of preferred stock, net of issuance cost of $194, shares						9,587,764
Issuance of common stock warrants	2,396			2,396
Accretion of redeemable convertible preferred stock to redemption value	(3,738)			(3,738)
Temporary equity, accretion of redeemable convertible preferred stock to redemption value						3,738
Net loss	(18,339)				(18,339)
Temporary Equity, Ending Balance at Dec. 31, 2014						34,098	48,783
Stockholders Equity, Ending Balance at Dec. 31, 2014	(84,766)			29,204	(113,970)
Temporary Equity, Ending Balance, Shares at Dec. 31, 2014						9,587,764	23,385,029
Stockholders Equity, Ending Balance, Shares at Dec. 31, 2014			2,074,030
Exercise of stock options	187			187
Exercise of stock options, Shares			355,965
Stock-based compensation	1,205			1,205
Accretion of redeemable convertible preferred stock to redemption value	(2,574)			(2,574)
Temporary equity, accretion of redeemable convertible preferred stock to redemption value						2,574
Preferred stock conversion to common stock upon the IPO	85,455		33	85,422		(36,672)	(48,783)
Preferred stock conversion to common stock upon the IPO, Shares			32,972,793			(9,587,764)	(23,385,029)
Issuance of common stock upon the IPO, net of issuance costs of $9,801 (unaudited)	58,425		9	58,416
Issuance of common stock upon the IPO, net of issuance costs of $9,801 (unaudited, Shares			8,528,306
Reclassification due to re-incorporation upon the IPO (unaudited)			2	(2)
Deemed dividend to common stock warrant holder (unaudited)	(197)			(197)
Increase in value of common stock warrant due to modification (unaudited)	197			197
Net loss	(14,099)				(14,099)
Stockholders Equity, Ending Balance at Sep. 30, 2015	$ 43,833		$ 44	$ 171,858	$ (128,069)
Temporary Equity, Ending Balance, Shares at Sep. 30, 2015						0	0
Stockholders Equity, Ending Balance, Shares at Sep. 30, 2015			43,931,094

Condensed Consolidated Statements of Redeemable and Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) (Unaudited) (USD $) In Thousands, unless otherwise specified	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014 Redeemable Convertible Preferred Stock [Member]
Issuance of preferred stock, issuance cost		$ 194
Issuance of common stock upon the IPO, issuance costs	$ 9,801

Condensed Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (14,099)	$ (16,351)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	210	272
Gain on disposal of equipment		3
Equity in loss of unconsolidated entity		932
Loss related to amendment of Bioceres funding agreement		1,450
Stock-based compensation	1,205	595
Common stock warrants issued for services		93
Change in fair value of derivative liabilities related to convertible promissory notes	845	621
Gain on expiration of warrant and derivative liability related to notes payable upon IPO	(437)
Accretion of debt discount	589	342
Changes in operating assets and liabilities:
Accounts receivable	357	591
Amounts due from related parties		100
Unbilled revenue	(51)	(821)
Inventories	(157)	550
Prepaid expenses and other current assets	(375)	39
Other noncurrent assets	(43)
Accounts payable and accrued expenses	1,676	60
Amounts due to related parties	(41)	(151)
Unearned revenue	(842)	(454)
Net cash used in operating activities	(11,163)	(12,129)
CASH FLOWS FROM INVESTING ACTIVITIES:
Cost method investment		(1,450)
Proceeds from sale of property and equipment		7
Purchases of property and equipment	(80)	(40)
Purchases of short-term investments	(11,290)
Net cash used in investing activities	(11,370)	(1,483)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock upon IPO	68,226
Payments of IPO issuance costs	(8,054)	(9)
Proceeds from issuance of notes payable	20,000
Payments of debt issuance costs	(290)
Proceeds from exercise of stock options	168	6
Proceeds from issuance of redeemable convertible preferred stock and common stock warrants, net of issuance costs		32,845
Payments on notes payable to related party	(8,000)
Payments on notes payable and convertible promissory notes	(3,122)	(836)
Capital lease payments		(59)
Net cash provided by financing activities	68,928	31,947
Net increase in cash and cash equivalents	46,395	18,335
Cash and cash equivalents — beginning of period	16,571	2,835
Cash and cash equivalents — end of period	62,966	21,170
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	1,411	571
Cash paid for income taxes	149	83
NONCASH INVESTING AND FINANCING ACTIVITIES:
Accretion of redeemable convertible preferred stock	2,574	2,088
Purchases of property and equipment included in accounts payable and accrued expenses	1
Deferred offering costs included in accounts payable and accrued expenses	155	214
Reclassification of deferred IPO costs to equity	5,026
Deemed dividend to common stock warrant holder	197
Issuance of warrants and derivatives	437
Stock option exercise cost included in accounts receivable	19
Conversion of preferred stock to common stock upon IPO	$ 85,455

Description of Business and Significant Accounting Policies

9 Months Ended

Sep. 30, 2015

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Description of Business and Significant Accounting Policies

1. Description of Business and Significant Accounting Policies

Organization

Arcadia Biosciences, Inc. (the “Company” or “we” or “our” or “us”), was incorporated in the state of Arizona in 2002 and maintains its headquarters in Davis, California, with additional facilities in Seattle, Washington; Phoenix, Arizona; and American Falls, Idaho. The Company was reincorporated in Delaware in March 2015.

The Company pursues agriculture-based biotechnology business opportunities that improve the environment and human health. The Company is an agricultural biotechnology trait company with an extensive and diversified portfolio of late-stage crop productivity and product quality traits addressing multiple crops that supply the global food and feed markets. Its traits are focused on high-value enhancements that increase crop yields by enabling plants to more efficiently manage environmental and nutrient stresses, and that enhance the quality and value of agricultural products.

In February 2012, the Company formed Verdeca LLC (“Verdeca,” see Note 3), which is jointly owned with Bioceres, Inc., a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres, S.A. is an agricultural investment and development cooperative. Verdeca was formed to develop and deregulate soybean varieties using both partners’ agricultural technologies.

Reverse Stock Split

In April 2015, the Company’s board of directors approved a certificate of amendment of the Company’s amended and restated certificate of incorporation to effect a reverse split of the Company’s issued and outstanding common stock at a one-for-four ratio. In May 2015, the Company’s stockholders approved the certificate of amendment, and on May 8, 2015, the Company filed the certificate of amendment with the Secretary of State of Delaware to effect the reverse split. The par value and authorized shares of common stock and convertible preferred stock were not adjusted as a result of the reverse split. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the financial statements have been retroactively adjusted to reflect the reverse stock split for all periods presented. The financial statements have also been retroactively adjusted to reflect a proportional adjustment to the conversion ratio for each series of redeemable convertible preferred stock and convertible preferred stock.

Initial Public Offering

In May 2015, the Company completed an initial public offering (“IPO”), and subsequently in June 2015, the Company completed the sale of additional shares upon exercise of the underwriters’ over-allotment option. In connection with the IPO, the Company issued and sold 8,528,306 shares of common stock, at $8.00 per share, which raised $58.4 million in proceeds, net of underwriting discounts, commissions and offering expenses. At the closing of the IPO, all of the outstanding shares of convertible preferred stock and redeemable convertible preferred stock were automatically converted into 32,972,793 shares of common stock. Following the IPO, there were no shares of preferred stock outstanding.

In connection with the IPO, the Company amended and restated its Amended and Restated Certificate of Incorporation to change the authorized capital stock to 400,000,000 shares designated as common stock and 20,000,000 shares designated as preferred stock, all with a par value of $0.001 per share.

Unaudited Interim Financial Information

The interim condensed consolidated balance sheet at September 30, 2015, and the condensed consolidated statements of operations and comprehensive loss, and cash flows for the nine months ended September 30, 2015 and 2014 are unaudited. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”), and following the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of our financial information. The results of operations for the nine months ended September 30, 2015 are not necessarily indicative of the results to be expected for the year ending December 31, 2015 or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2014 included herein was derived from the audited consolidated financial statements as of that date. These financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the prospectus dated May 14, 2015 that forms a part of the Company’s Registration Statement on Form S-1, filed with the SEC pursuant to Rule 424 promulgated under the Securities Act of 1933, as amended.

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and Verdeca LLC. All intercompany balances and transactions have been eliminated in consolidation. The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities (“VIEs”). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE. For all periods presented, the Company has determined that it is the primary beneficiary of Verdeca, which is a VIE. The Company evaluates its relationships with the VIEs upon the occurrence of certain significant events that affect the design, structure or other factors pertinent to the primary beneficiary determination.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions in the Company’s condensed consolidated financial statements and notes thereto. Significant estimates and assumptions made by management included the determination of the provision for income taxes, costs to complete government grants and research contracts, the development period of revenue-generating technologies and the estimation of inventory reserves. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.

Deferred Offering Costs

Deferred offering costs, which consist of direct incremental legal, consulting, banking and accounting fees relating to the Company’s IPO, are capitalized. The deferred offering costs were subsequently offset against IPO proceeds upon the closing of the offering in May 2015. At December 31, 2014, the Company capitalized $2.8 million of deferred offering costs in other noncurrent assets on the consolidated balance sheet. There were no remaining amounts deferred at September 30, 2015 pertaining to the IPO.

Net Loss per Share

Basic net loss per share, which excludes dilution, is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock, such as stock options, convertible promissory notes, convertible preferred stock, redeemable convertible preferred stock and warrants, result in the issuance of common stock which share in the losses of the Company. Certain potential shares of common stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive and would be to reduce the loss per share. The Company’s convertible preferred stock are considered to be participating securities as they are entitled to participate in undistributed earnings with shares of common stock. Due to net losses, there is no impact on earnings per share calculation in applying the two-class method since the participating securities have no legal requirement to share in any losses.

SONOVA ® GLA Safflower Oil Inventory

Proprietary safflower plants are grown, producing seed with high gamma linolenic acid (GLA) content. This seed is used for subsequent plantings or processed, and sold as GLA oil. Amounts inventoried consist primarily of fees paid to contracted cooperators to grow the crops and costs to process and store harvested seed. Inventory costs are tracked on a lot-identified basis, valued at the lower of cost or market, and are included as cost of product revenues when sold. The Company provides for inventory reserves when conditions indicate that the selling price may be less than cost due to physical deterioration, obsolescence, changes in price levels, or other factors. Additionally, the Company provides reserves for excess and slow-moving inventory on hand that is not expected to be sold within a reasonable period to reduce the carrying amount to its estimated net realizable value. The reserves are based upon estimates about future demand from the Company’s customers and distributors and market conditions. The Company had inventory reserves of $1.7 million as of September 30, 2015 and December 31, 2014, relating to reserves recorded in 2014 primarily as a result of changes in conditions of specific customers and regulatory delays for the use of its Sonova products by certain new industries.

The inventories—current line item in the condensed consolidated balance sheet consists of the cost of oil inventory forecasted to be sold in the next 12 months, as of the balance sheet date. The inventories—noncurrent line item consists of oil and seed inventory expected to be used in production or sold beyond the next 12 months, as of the balance sheet date.

Raw materials inventories consist primarily of seed production costs incurred by our contracted cooperators. Finished goods inventories consist of GLA oil that is available for sale. Combined current and non-current inventories are categorized as follows (in thousands):

	September 30, 2015		December 31, 2014
Raw materials	$	1,183	$	1,004
Finished goods		1,547		1,569
Inventories	$	2,730	$	2,573

Concentrations of Credit Risk

Financial instruments that potentially subject us to a concentration of credit risk consist of cash, money market funds and fixed income investments. Although we deposit our cash with multiple financial institutions, our deposits, at times, exceed federally insured limits. We invest in fixed income securities that are of high-credit quality.

Cash Equivalents

We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. As of September 30, 2015 and December 31, 2014, cash and cash equivalents consist of cash deposited with banks, money market funds and investments that mature within three months of their purchase.

Fair Value of Financial Instruments

Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity, associated with the inputs to the valuation of these assets or liabilities are as follows:

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date.

Level 2 inputs are observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 inputs are unobservable inputs for the asset or liability.

The carrying values of the Company’s financial instruments, including cash equivalents, accounts receivable, and accounts payable, approximated their fair values due to the short period of time to maturity or repayment.

As of September 30, 2015, the Company had investments in fixed income securities with maturities of one year or less from date of purchase, which are considered available-for-sale and recorded in short-term investments in the Consolidated Balance Sheets. The Company had an insignificant amount of unrealized gains or losses and did not recognize any other-than-temporary impairments. The Company did not have investments in fixed income securities at December 31, 2014.

The Company’s cash equivalents and investments in fixed income securities as of September 30, 2015 were as follows:

	Fair Value Measurements at September 30, 2015
(Dollars in thousands)	Level 1		Level 2		Level 3		Total
Assets at Fair Value
Cash equivalents:
Money market funds	$	45,697	$	—	$	—	$	45,697
Commercial paper		4,999		—		—		4,999
U.S. government agency securities		2,001		—		—		2,001
Short-term investments:
Commercial paper		—		1,000		—		1,000
U.S. government securities		—		5,040		—		5,040
U.S. government agency securities		—		5,250		—		5,250
Total Assets at Fair Value	$	52,697	$	11,290	$	—	$	63,987

The carrying values of the Company’s promissory notes, convertible promissory notes, and notes payable approximate their fair values for the three and nine months ended September 30, 2015 and 2014 as the market rates currently available to the Company and other assumptions have not changed significantly. These were classified as Level 2.

The Company’s Level 3 liabilities measured and recorded on a recurring basis consist of derivative liabilities related to the convertible promissory note. The following table sets forth a summary of the changes in the fair value and other adjustments of these derivative liabilities (in thousands):

	Three Months Ended September 30,					Nine Months Ended September 30,
	2015			2014		2015		2014
Beginning balance	$	2,688		$	994	$	1,580	$	1,192
Change in fair value and other adjustments		(263	)		596		845		398
Ending balance	$	2,425		$	1,590	$	2,425	$	1,590

Contingent Liability Related to the Anawah Acquisition

On June 15, 2005, the Company completed its agreement and plan of merger and reorganization with Anawah, Inc. (“Anawah” or “Sellers”), to purchase the Sellers’ food and agricultural research company through a stock purchase. Pursuant to the merger with Anawah, the Company incurred a contingent liability not to exceed $5.0 million. This liability represents amounts to be paid to Anawah’s previous stockholders for cash collected on revenue recognized by the Company upon commercial sale of certain specific products developed using technology acquired in the purchase. As of December 31, 2010, the Company ceased activities relating to three of the six Anawah product programs and, as a result, reduced the contingent liability to $3.0 million. As of September 30, 2015, the Company believes the contingent liability is appropriate as it continues to pursue three development programs using this technology.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. In August 2015, FASB issued ASU 2015-14, Revenue from Contracts with Customers, which defers the effective date by one year. The new standard will be effective for the Company on January 1, 2018, which is the effective date for public companies. Early application with an effective date of January 1, 2017 is permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 and ASU 2015-14 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which provides guidance on determining when and how to disclose going-concern uncertainties in the consolidated financial statements. The new standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of the date the consolidated financial statements are issued. An entity must provide certain disclosures if “conditions or events raise substantial doubt about the entity’s ability to continue as a going concern.” The ASU applies to all entities and is effective for annual periods ending after December 15, 2016, and interim periods thereafter, with early adoption permitted. The Company does not anticipate a material change to its consolidated financial statements upon the adoption of this ASU. However, it will be required to evaluate and determine if further disclosure is necessary at each balance sheet date.

In February 2015, the FASB issued ASU 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis. The amendments significantly change the consolidation analysis required under U.S. GAAP. Reporting entities will need to reevaluate all their previous consolidation conclusions. The new standard will be effective for the Company on January 1, 2016. The Company does not anticipate that the adoption of this ASU will materially change the presentation of its consolidated financial statements.

In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs, which requires debt issuance costs to be presented in the balance sheet as a direct deduction from the associated debt liability. ASU 2015-03 will not change the amortization of debt issuance costs, which will continue to follow the existing accounting guidance. ASU 2015-03 will be effective for interim and annual reporting periods beginning after December 15, 2015. Early application is permitted. The Company is currently evaluating the impact of the adoption of ASU 2015-03 on its operating results and financial position.

In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory, which applies guidance on subsequent measurement of inventory. An entity should measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonable predictable costs of completion, disposal and transportation. The guidance excludes inventory measured using LIFO or the retail inventory method. ASU 2015-11 will be effective for interim and annual reporting periods beginning after December 15, 2016. Early application is permitted. The Company does not anticipate that the adoption of this ASU will materially change the presentation of its consolidated financial statements.

- Definition

The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.

+ References+ Details

Investment in Unconsolidated Entity	9 Months Ended
Investment in Unconsolidated Entity	Sep. 30, 2015
Equity Method Investments And Joint Ventures [Abstract]
Investment in Unconsolidated Entity	2. Investment in Unconsolidated Entity The Company owns a 35% ownership position in Limagrain Cereal Seeds LLC (“LCS”). The remaining 65% of LCS is owned by Vilmorin & Cie, a major global producer and marketer of field crop and vegetable seeds and affiliate of Groupe Limagrain (“Limagrain”), through its wholly owned subsidiary, Vilmorin USA (“VUSA”). LCS improves and develops new wheat and barley varieties utilizing genetic and breeding resources, as well as advanced technologies from Limagrain and the Company. Funding for LCS comes from an initial pro rata equity investment from each partner and with subsequent financing in the form of debt from VUSA. As of September 30, 2015, the debt balance was $17.8 million with a maturity date of January 15, 2016. While it is the Company’s expectation that VUSA will provide LCS with additional debt financing and extend maturity for repayment as needed, should additional capital in the form of equity be necessary to support the operations of LCS, the Company has the option to fund its pro rata share of such cash or elect to have its ownership percentage diluted. As of September 30, 2015 and December 31, 2014, the Company’s investment in LCS has been reduced to $0 as a result of its equity method loss recognition.

- Definition

The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.

+ References+ Details

Variable Interest Entity	9 Months Ended
Variable Interest Entity	Sep. 30, 2015
Equity Method Investments And Joint Ventures [Abstract]
Variable Interest Entity	3. Variable Interest Entity In February 2012, the Company formed Verdeca, which is jointly owned with Bioceres, Inc., a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres, S.A. is an agricultural investment and development company owned by approximately 230 shareholders, including some of South America’s largest soybean growers. Verdeca was formed to develop and license soybean traits using both partners’ agricultural technologies. Both the Company and Bioceres, Inc. incur expenses in support of specific agreed activities on behalf of Verdeca, as defined by joint work plans, which apply fair market value to each partner’s activities. Verdeca is not the primary obligor for these activities performed by the Company or Bioceres, Inc. Unequal contributions of services are equalized by the partners through cash payments. An agreement executed in conjunction with the formation of Verdeca specifies that if Bioceres Inc. determines it requires cash to fund its contributed services (subject to certain annual limits), Bioceres, S.A. may elect to sell shares of its common stock to the Company for an amount not exceeding $5.0 million in the aggregate over a four-year period. The Company determined that its commitment to purchase common stock in Bioceres, S.A. as a means to provide capital to Verdeca resulted in a de facto agency relationship between the Company and Bioceres, Inc. The Company considers qualitative factors in assessing the primary beneficiary which include understanding the purpose and design of the VIE, associated risks that the VIE creates, activities that could be directed by the Company, and the expected relative impact of those activities on the economic performance of the VIE. Based on an evaluation of these factors, the Company concluded that it is the primary beneficiary of Verdeca. As a result of the agreement to fund future contributions by Bioceres, Inc., the Company purchased common stock of Bioceres, S.A. in the aggregate amount of $2.0 million between January 2013 and August 2014. The Company’s remaining maximum commitment to purchase stock in Bioceres, S.A. under the original funding agreement amounted to $2.0 million for 2014 and $1.2 million for 2015. In September 2014, the Company and Bioceres, S.A. entered into an agreement to reduce the annual commitment for 2014 to $0.5 million from the original $2.0 million and to eliminate the 2015 commitment amount of $1.2 million. In consideration for these amendments, the Company surrendered 1,832 shares of Bioceres, S.A. held by the Company. The Company recorded an expense of $1.5 million related to this agreement, which is classified as research and development expense in the consolidated statement of operations for the quarter ended September 30, 2014. In addition, the Company has a right to require Bioceres, S.A. to repurchase any shares of common stock then owned by the Company upon the occurrence of certain events specified in the agreement, and similarly, Bioceres, S.A. has the right to require the Company to sell back any shares of common stock owned by the Company under certain circumstances. Under the terms of the joint development agreement, the Company has incurred direct expenses and allocated overhead in the amount of $0.9 million, $1.2 million, $0.2 million, and $0.7 million for the three and nine months ended September 30, 2015 and 2014, respectively. The amounts pertaining to 2015 were inclusive of subcontracted research services related to the development of soybean events in the amount of $0.7 million with Bioceres S.A. and Bioceres Semillas, S.A., a subsidiary of S.A. under an agreement effective July 2015. Per the agreement, the Company may pay for these services with a combination of cash and Bioceres S.A. shares.

Debt

9 Months Ended

Sep. 30, 2015

Debt Disclosure [Abstract]

Debt

4. Debt

Long-term Debt

Long-term debt consisted of the following (in thousands):

	September 30, 2015		December 31, 2014
Notes payable	$	19,462	$	—
Note payable to related party		—		8,000
Promissory note		—		1,924
Total		19,462		9,924
Less current portion		—		(1,055	)
Long-term portion	$	19,462	$	8,869

In July 2012, a 36-month $8.0 million term note was executed with Moral Compass Corporation (“MCC”), the Company’s largest stockholder, and was subordinate to the promissory notes and convertible promissory notes. The interest rate on the loan was prime plus 2%, with interest only paid monthly in arrears. The principal was due in full at maturity in July 2015. On November 10, 2014, the Company and MCC entered into an amendment to the $8.0 million term loan under which the maturity date was extended to the first to occur of the following dates: (i) April 1, 2016, (ii) the date of an Event of Default, or (iii) a date designated by MCC, by notice to the Company, no earlier than the 20th day following consummation by the Company of an equity financing with gross proceeds to the Company of at least $50 million. In addition, the interest rate remained at prime plus 2% through December 31, 2014, and was amended to increase to 11% per annum thereafter until maturity. The balance of the note, inclusive of accrued interest, was approximately $8.0 million as of December 31, 2014. Accrued interest of $36,000 was recorded in amounts due to related parties on the balance sheet as of December 31, 2014. This term note, including the principal balance of $8.0 million and accrued interest and prepayment fee of $0.1 million, was paid off in full in April 2015.

Promissory notes were executed with an unrelated party in August 2013 and November 2013 in the amounts of $2.0 million and $1.1 million, respectively. The interest rate on the notes was 10% with principal and interest due in 36 equal monthly installments over the course of their respective three-year terms. These notes, including the aggregate outstanding principal balance of $1.6 million and accrued interest and prepayment fee of $44,000, were paid off in full in April 2015.

In April 2015, the Company entered into a loan and security agreement with an unrelated party, under which the Company incurred an aggregate principal amount of $20.0 million in term loan borrowings (the “Term Loans”). Under this loan agreement, interest on the Term Loans accrues at a rate per annum equal to the greater of (i) 9.0% and (ii) a fluctuating rate of interest equal to three-month LIBOR as in effect from time to time plus 8.74%. The Company is required to make interest-only payments under this agreement from the drawdown dates through April 30, 2016, subject to certain conditions for extension to October 31, 2016. After this date, it is required to make equal monthly payments of principal and interest so that all outstanding principal amounts and accrued interest will be repaid by November 1, 2018. This agreement provides for a right of prepayment with associated prepayment fees. Upon the maturity date or the date on which the Term Loans are prepaid in whole or in part, the Company owes an additional end-of-term payment of $0.6 million to the lenders.

The loan and security agreement includes customary covenants for credit facilities of this type. In addition, the agreement contains a financial covenant with respect to quarterly revenue targets, which shall not be less than 80% of the projected revenue for such periods, or cash and cash equivalents on hand which shall be at least 50% of the outstanding loan amount. As of September 30, 2015, the Company is in compliance with such covenants. The obligations under the loan agreement are secured by substantially all of the Company’s assets. In July 2015, the Company amended the loan agreement to include certain intellectual property rights in exchange for a waiver of the Company’s obligation to obtain a subordination agreement from Mahyco International Pte, Ltd. (“Mahyco International”) with respect to the indebtedness the Company owes to Mahyco International. If any of these events of default occurs, the lenders may accelerate and declare to be immediately due and payable the outstanding principal amount of the Term Loans and the Company’s other payment obligations under the agreement. In the case of a bankruptcy or insolvency event of default, the outstanding principal amount of the Term Loans and the Company’s other payment obligations under the loan agreement automatically are accelerated and become due and payable. In addition, if an event of default occurs and is continuing under the loan agreement, the lenders may exercise certain additional secured creditor remedies against the Company and against the assets securing the Company’s obligations under the agreement.

As part of the loan and security arrangement, the Company also issued the lenders warrants to purchase 1,503,760 shares of its common stock at an exercise price of $5.32 per share, which were only exercisable in the event that an IPO was not completed prior to September 30, 2015 and would remain exercisable until November 1, 2018. The Company initially recorded $0.4 million for the fair value of the warrants as a liability in the consolidated balance sheet, which was subject to subsequent remeasurement for changes in fair value until exercise or expiration. In addition, the Company concluded that the interest rate adjustment upon non-occurrence of an IPO is an embedded derivative and recorded $81,000 for the fair value of the embedded derivative as a liability, which was subject to subsequent remeasurement for changes in fair value until exercise or expiration. The proceeds received under the Term Loans, less fees paid to the lender of $0.3 million, were allocated to the warrant liability and the embedded derivative liability based on their initial fair values with the residual amount recorded as notes payable. The resulting debt discount will be amortized as interest expense over the term of the Term Loans using the effective interest method. The interest expense related to the debt discount was $0.1 million and $0.2 million for the three and nine months ended September 30, 2015.

In May 2015, upon the completion of the IPO, the warrants were terminated and the right to adjust interest rate upon non-occurrence of an IPO was relinquished. As such, the Company reclassified the initial fair value of the warrants and the embedded derivative of $0.4 million to other income. The Company recognized interest expense inclusive of the debt discount related to the combined Term Loans of $0.6 million and $1.0 million for the three and nine months ended September 30, 2015.

Convertible Promissory Notes

A note and warrant purchase agreement was executed in September 2013, with Mahyco International, an affiliate of Maharashtra Hybrid Seeds Company Ltd. (“Mahyco”), which is a licensee of the Company’s technologies. The Company issued two notes under this agreement in the amounts of $0.5 million in September 2013 and $4.5 million in December 2013. The interest on the notes is prime plus 2%, compounded monthly over the course of the five-year terms ending September and December 2018, and is payable on the maturity dates. At any time during the term, the lender may convert all or part of the outstanding balance of the notes (including principal and accrued but unpaid interest) into common stock of the Company at $16.52 per share through December 2016 and at 90% of the most recent offering thereafter.

At its option, Mahyco International may offset future fee payments due from Mahyco to the Company against the outstanding balance of the notes (including principal and accrued but unpaid interest). Mahyco International has the right to demand immediate settlement of a portion of the outstanding balance of the convertible promissory notes, the amount of which shall be mutually agreed by the Company and the lender prior to such settlement. The Company recorded a derivative liability for the initial fair value of the settlement obligation. The lender has the right, at its option, to place another $5.0 million of convertible debt with the Company during the five-year term. The Company recorded a derivative liability for the initial fair value of the Company’s obligation to issue the additional $5.0 million of convertible promissory notes. Changes in the fair value of the derivative liabilities are recorded to other income (expense), net in the condensed consolidated statement of operations.

The Company also issued to the lender a warrant to purchase 75,666 shares of common stock at an exercise price of $16.52. The warrant was issued in December 2013, vested immediately and remains exercisable throughout the five-year term. The Company allocated the gross proceeds to the derivative liabilities based on their initial fair values and the remainder of the proceeds to the convertible promissory note and warrants on a relative fair value basis. The amount allocated to the common stock warrant was recorded as a debt discount to be amortized as interest expense over the estimated term of the loan agreement using the effective interest rate method. The Company recognized interest expense related to the convertible promissory note of $0.2 million, $0.6 million, $0.2 million and $0.7 million for the three and nine months ended September 30, 2015 and 2014, respectively. Of the total interest expense recognized, $0.1 million, $0.4 million, $0.2 million and $0.5 million were related to the debt discount for the three and nine months ended September 30, 2015 and 2014, respectively. In March 2015, the parties amended the warrant to clarify the meaning of a reorganization event. The Company accounted for the amendment as a modification with the incremental increase in fair value of $0.2 million as of the amendment date, which was accounted for as a deemed dividend to the warrant holder.

Stock-Based Compensation

9 Months Ended

Sep. 30, 2015

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

5. Stock-Based Compensation

Stock Incentive Plans

The Company has two equity incentive plans: the 2006 Stock Plan (“2006 Plan”) and the 2015 Omnibus Equity Incentive Plan (“2015 Plan”).

In 2006, the Company adopted the 2006 Plan, which provided for the granting of stock options to executives, employees, and other service providers under terms and provisions established by the Board of Directors. The Company granted options under the 2006 Plan until May 2015, when it was terminated as to future awards, although it continues to govern the terms of options that remain outstanding under the 2006 Plan. Certain options vested upon completion of the IPO and the remaining unvested options vest over original service periods between two-and-a-quarter and four years. The 2015 Plan became effective upon the IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 3,087,729 shares of common stock reserved for future issuance, which included 212,729 shares under the 2006 Plan that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant, beginning on January 1, 2016. In addition, shares subject to awards under the 2006 Plan that are forfeited or terminated will be added to the 2015 Plan. The 2015 Plan provides for the grant of incentive stock options (“ISOs”), nonstatutory stock options (“NSOs”), restricted stock awards, stock units, stock appreciation rights, and other forms of equity compensation, all of which may be granted to employees, officers, non-employee directors, and consultants. The ISOs and NSOs will be granted at a price per share not less than the fair value at date of grant. Options granted generally vest over a four-year period, with 25% vesting at the end of one year and the remaining vesting monthly thereafter. Options granted generally are exercisable for up to 10 years.

As of September 30, 2015, a total of 3,089,340 shares of common stock were reserved for issuance under the 2015 Plan, of which 3,044,340 shares of common stock are available for future grant. In connection with the IPO, and as contemplated by the Company’s Director Compensation Policy, the Company granted options to purchase an aggregate of 45,000 shares to three new members of the Board of Directors who joined the Board in connection with the IPO. As of September 30, 2015, a total of 3,699,534 and 45,000 options are outstanding under the 2006 and 2015 Plans, respectively.

A summary of activity under the stock incentive plans is as follows (in thousands, except share data and price per share):

	Shares Subject to Outstanding Options			Weighted- Average Exercise Price Per Share		Aggregate Intrinsic Value
Outstanding — Balance at December 31, 2014		3,759,839		$	3.00	$	12,499
Options granted		352,493			7.30
Options exercised		(355,965	)		0.53
Options cancelled and forfeited		(11,833	)		7.92
Outstanding — Balance at September 30, 2015		3,744,534		$	3.61	$	4,332
Options vested and exercisable — September 30, 2015		3,359,944		$	3.20	$	4,322

As of September 30, 2015, there was $1.4 million of unrecognized compensation cost related to unvested stock-based compensation grants that will be recognized over the weighted-average remaining recognition period of 2.3 years.

The weighted-average estimated grant-date fair value of employee stock options granted during the three and nine months ended September 30, 2015 were $0 and $4.61, respectively. There were no options granted during the three months ended September 30, 2015, and the three and nine months ended September 30, 2014.

Employee Stock Purchase Plan

Concurrent with the effectiveness of the Company’s registration statement on Form S-1 on May 14, 2015, the Company’s 2015 Employee Stock Purchase Plan (“ESPP”) became effective. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations. After the first offering period, which began on May 14, 2015 and ends on February 1, 2016, the ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last day of the offering period. The initial number of shares of common stock reserved for issuance under the ESPP is 625,000, and the ESPP provides for automatic annual increases in the shares available for purchase beginning on January 1, 2016. As of September 30, 2015, no shares had been issued under the ESPP.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References+ Details

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	6. Income Taxes Income tax expense during interim periods is based on applying an estimated annual effective income tax rate to year-to-date income, plus any significant unusual or infrequently occurring items that are recorded in the interim period. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in various jurisdictions, permanent and temporary differences, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known or as the tax environment changes. The interim financial statement provision for income taxes expense is different from the amounts computed by applying the United States federal statutory income tax rate of 34%. The Company’s effective tax rate (ETR) was 2.1% and -1.6% for the three and nine months ended September 30, 2015, respectively, and -0.6% and -1.5% for the three and nine months ended September 30, 2014, respectively. The difference between the effective tax rate and the federal statutory rate of 34% was primarily due to the full valuation allowance recorded on the Company’s net deferred tax assets and foreign withholding taxes. As of September 30, 2015, there have been no material changes to our uncertain tax positions.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References+ Details

Net Loss per Share

9 Months Ended

Sep. 30, 2015

Earnings Per Share [Abstract]

Net Loss per Share

7. Net Loss per Share

Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per share attributable to common stockholders is computed giving effect to all potentially dilutive common shares, including common stock issuable upon exercise of stock options and warrants and conversion of convertible promissory notes, redeemable convertible preferred stock and convertible preferred stock. As the Company had net losses for the three and nine months ended September 30, 2015 and 2014, all potentially dilutive common shares were determined to be anti-dilutive.

Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares):

	Nine Months Ended September 30,
	2015		2014
Convertible preferred stock		—		23,385,029
Redeemable convertible preferred stock		—		9,587,764
Options to purchase common stock		3,744,534		3,642,971
Warrants to purchase common stock		1,336,894		1,336,894
Convertible promissory notes		320,464		304,108
Total		5,401,892		38,256,766

- Definition

The entire disclosure for earnings per share.

+ References+ Details

Related-Party Transactions	9 Months Ended
Related-Party Transactions	Sep. 30, 2015
Related Party Transactions [Abstract]
Related-Party Transactions	8. Related-Party Transactions The Company’s related parties include MCC, Blue Horse Labs, Inc. (“BHL”), and Limagrain. BHL is deemed a related party as a result of its existing contractual relationship with the Company and because a Director of the Company also serves as the Treasurer of BHL and as an Officer and Director of MCC, the Company’s controlling stockholder as of September 30, 2015. Transactions with related parties are reflected in the condensed consolidated financial statements under amounts due to or from related parties and notes payable to related party. Outlined below are details of agreements between the Company and its related parties: A term note was executed with MCC in July 2012 for $8.0 million (see Note 4). The principal balance is included in the December 31, 2014 consolidated balance sheets as notes payable to related party and the related accrued interest is included in amounts due to related parties. This note was paid off in full in April 2015. Under a license agreement executed in 2003 and amended in 2009, BHL receives a single-digit royalty from the Company when revenue has been collected on product sales or for license payments from third parties that involve certain intellectual property developed under research funding from BHL. Royalty fees due to BHL were $15,000 and $21,000 as of September 30, 2015 and December 31, 2014, respectively, and are included in the consolidated balance sheets as amounts due to related parties. License agreements were executed with Limagrain, a stockholder of the Company, in September 2009 and February 2011. The agreements license certain of the Company’s traits to Limagrain and include up-front license fees, annual license fees, milestone fees and value-sharing payments. The Company recognized $23,000 of revenue under these agreements in each of the three months ended September 30, 2015 and 2014 and $68,000 in each of the nine months ended September 30, 2015 and 2014. No amounts were due from Limagrain as of September 30, 2015 and December 31, 2014.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References+ Details

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	9. Subsequent Events The Company has reviewed and evaluated subsequent events through November 5, 2015, the date the condensed consolidated financial statements were available to be issued.

Description of Business and Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2015

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Organization

Reverse Stock Split

Initial Public Offering

Unaudited Interim Financial Information

Basis of Presentation and Principles of Consolidation

Use of Estimates

Deferred Offering Costs

Net Loss per Share

SONOVA® GLA Safflower Oil Inventory

SONOVA ® GLA Safflower Oil Inventory

	September 30, 2015		December 31, 2014
Raw materials	$	1,183	$	1,004
Finished goods		1,547		1,569
Inventories	$	2,730	$	2,573

Fair Value of Financial Instruments

Concentrations of Credit Risk

Cash Equivalents

Fair Value of Financial Instruments

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date.

Level 3 inputs are unobservable inputs for the asset or liability.

The Company’s cash equivalents and investments in fixed income securities as of September 30, 2015 were as follows:

	Fair Value Measurements at September 30, 2015
(Dollars in thousands)	Level 1		Level 2		Level 3		Total
Assets at Fair Value
Cash equivalents:
Money market funds	$	45,697	$	—	$	—	$	45,697
Commercial paper		4,999		—		—		4,999
U.S. government agency securities		2,001		—		—		2,001
Short-term investments:
Commercial paper		—		1,000		—		1,000
U.S. government securities		—		5,040		—		5,040
U.S. government agency securities		—		5,250		—		5,250
Total Assets at Fair Value	$	52,697	$	11,290	$	—	$	63,987

	Three Months Ended September 30,					Nine Months Ended September 30,
	2015			2014		2015		2014
Beginning balance	$	2,688		$	994	$	1,580	$	1,192
Change in fair value and other adjustments		(263	)		596		845		398
Ending balance	$	2,425		$	1,590	$	2,425	$	1,590

Concentrations of Credit Risk

Cash Equivalents

Contingent Liability Related to the Anawah Acquisition

Recent Accounting Pronouncements

Description of Business and Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2015

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Summary of Current and Non-current Inventories

Combined current and non-current inventories are categorized as follows (in thousands):

	September 30, 2015		December 31, 2014
Raw materials	$	1,183	$	1,004
Finished goods		1,547		1,569
Inventories	$	2,730	$	2,573

Schedule of Cash Equivalents and Investments in Fixed Income Securities

The Company’s cash equivalents and investments in fixed income securities as of September 30, 2015 were as follows:

	Fair Value Measurements at September 30, 2015
(Dollars in thousands)	Level 1		Level 2		Level 3		Total
Assets at Fair Value
Cash equivalents:
Money market funds	$	45,697	$	—	$	—	$	45,697
Commercial paper		4,999		—		—		4,999
U.S. government agency securities		2,001		—		—		2,001
Short-term investments:
Commercial paper		—		1,000		—		1,000
U.S. government securities		—		5,040		—		5,040
U.S. government agency securities		—		5,250		—		5,250
Total Assets at Fair Value	$	52,697	$	11,290	$	—	$	63,987

Summary of Changes in Fair Value and Other Adjustments of Derivative Liabilities

The following table sets forth a summary of the changes in the fair value and other adjustments of these derivative liabilities (in thousands):

	Three Months Ended September 30,					Nine Months Ended September 30,
	2015			2014		2015		2014
Beginning balance	$	2,688		$	994	$	1,580	$	1,192
Change in fair value and other adjustments		(263	)		596		845		398
Ending balance	$	2,425		$	1,590	$	2,425	$	1,590

- Definition

Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.

+ References+ Details

Debt (Tables)

9 Months Ended

Sep. 30, 2015

Debt Disclosure [Abstract]

Summary of Long-Term Debt

Long-term debt consisted of the following (in thousands):

	September 30, 2015		December 31, 2014
Notes payable	$	19,462	$	—
Note payable to related party		—		8,000
Promissory note		—		1,924
Total		19,462		9,924
Less current portion		—		(1,055	)
Long-term portion	$	19,462	$	8,869

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2015

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Activity Under Stock Incentive Plans

A summary of activity under the stock incentive plans is as follows (in thousands, except share data and price per share):

	Shares Subject to Outstanding Options			Weighted- Average Exercise Price Per Share		Aggregate Intrinsic Value
Outstanding — Balance at December 31, 2014		3,759,839		$	3.00	$	12,499
Options granted		352,493			7.30
Options exercised		(355,965	)		0.53
Options cancelled and forfeited		(11,833	)		7.92
Outstanding — Balance at September 30, 2015		3,744,534		$	3.61	$	4,332
Options vested and exercisable — September 30, 2015		3,359,944		$	3.20	$	4,322

Net Loss per Share (Tables)

9 Months Ended

Sep. 30, 2015

Earnings Per Share [Abstract]

Schedule of Securities Not Included in Diluted per Share Calculations

Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares):

	Nine Months Ended September 30,
	2015		2014
Convertible preferred stock		—		23,385,029
Redeemable convertible preferred stock		—		9,587,764
Options to purchase common stock		3,744,534		3,642,971
Warrants to purchase common stock		1,336,894		1,336,894
Convertible promissory notes		320,464		304,108
Total		5,401,892		38,256,766

Description of Business and Significant Accounting Policies - Additional Information (Detail) (USD $)	9 Months Ended	12 Months Ended		0 Months Ended	9 Months Ended		1 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	May 30, 2015	Dec. 31, 2010 Anawah Inc [Member] Program	Sep. 30, 2015 Anawah Inc [Member] Program	Jun. 15, 2005 Anawah Inc [Member] Maximum [Member]	May 30, 2015 IPO [Member]
Description Of Business And Summary Of Significant Accounting Policies [Line Items]
Inventory reserve	$ 1,700,000	$ 1,700,000
Place of incorporation	Arizona
Year of incorporation	2002
Place of reincorporation	Delaware
Date of reincorporation	2015-03
Reverse split of issued and outstanding common stock	one-for-four
Common stock, issued and sold							8,528,306
Common stock issued price per share							$ 8.00
Net proceeds from IPO	68,226,000						58,400,000
Convertible preferred stock, conversion basis	At the closing of the IPO, all of the outstanding shares of convertible preferred stock and redeemable convertible preferred stock were automatically converted into 32,972,793 shares of common stock.
Converted common stock			32,972,793
Preferred stock, outstanding	0	0	0
Amended and Restated common stock, shares authorized	400,000,000	140,000,000	400,000,000
Amended and Restated preferred stock, shares authorized	20,000,000	0	20,000,000
Amended and Restated common stock, shares par value	$ 0.001	$ 0.001	$ 0.001
Amended and Restated preferred stock, shares par value	$ 0.001	$ 0.001	$ 0.001
Deferred offering costs	0	2,800,000
Investment in fixed income securities		0
Unrealized gains or losses other than temporary impairments	0
Contingent liability				$ 3,000,000		$ 5,000,000
Date of merger and reorganization					Jun. 15, 2005
Restructuring activities, description					As of December 31, 2010, the Company ceased activities relating to three of the six Anawah product programs
Number of development programs \| Program				3	3
Number of development programs ceased \| Program				3

Description of Business and Significant Accounting Policies - Summary of Current and Non-current Inventories (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 1,183	$ 1,004
Finished goods	1,547	1,569
Inventories	$ 2,730	$ 2,573

Description of Business and Significant Accounting Policies - Schedule of Cash Equivalents and Investments in Fixed Income Securities (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2015
Assets at Fair Value
Short-term investments	$ 11,290
Total Assets at Fair Value	63,987
Fair Value Measurements, Level 1 [Member]
Assets at Fair Value
Total Assets at Fair Value	52,697
Fair Value Measurements, Level 2 [Member]
Assets at Fair Value
Total Assets at Fair Value	11,290
Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	45,697
Money Market Funds [Member] \| Fair Value Measurements, Level 1 [Member]
Assets at Fair Value
Cash equivalents	45,697
Commercial Paper [Member]
Assets at Fair Value
Cash equivalents	4,999
Short-term investments	1,000
Commercial Paper [Member] \| Fair Value Measurements, Level 1 [Member]
Assets at Fair Value
Cash equivalents	4,999
Commercial Paper [Member] \| Fair Value Measurements, Level 2 [Member]
Assets at Fair Value
Short-term investments	1,000
U.S. Government Securities [Member]
Assets at Fair Value
Short-term investments	5,040
U.S. Government Securities [Member] \| Fair Value Measurements, Level 2 [Member]
Assets at Fair Value
Short-term investments	5,040
U.S. Government Agency Securities [Member]
Assets at Fair Value
Cash equivalents	2,001
Short-term investments	5,250
U.S. Government Agency Securities [Member] \| Fair Value Measurements, Level 1 [Member]
Assets at Fair Value
Cash equivalents	2,001
U.S. Government Agency Securities [Member] \| Fair Value Measurements, Level 2 [Member]
Assets at Fair Value
Short-term investments	$ 5,250

Description of Business and Significant Accounting Policies - Summary of Changes in Fair Value and Other Adjustments of Derivative Liabilities (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Fair Value Assets And Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Abstract]
Beginning balance	$ 2,688	$ 994	$ 1,580	$ 1,192
Change in fair value and other adjustments	(263)	596	845	398
Ending balance	$ 2,425	$ 1,590	$ 2,425	$ 1,590

Investment in Unconsolidated Entity - Additional information (Detail) (Limagrain Cereal Seeds LLC [Member], USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Schedule of Equity Method Investments [Line Items]
Investment, ownership percentage	35.00%
Loss on investments	$ 0	$ 0
Vilmorin Cie [Member]
Schedule of Equity Method Investments [Line Items]
Investment, remaining ownership percentage	65.00%
Vilmorin USA [Member]
Schedule of Equity Method Investments [Line Items]
Debt balance	$ 17,800,000
Maturity date of debt	Jan. 15, 2016

- Definition

This item represents the net total realized and unrealized gain (loss) included in earnings for the period as a result of selling or holding marketable securities categorized as trading, available-for-sale, or held-to-maturity, including the unrealized holding gain (loss) of held-to-maturity securities transferred to the trading security category and the cumulative unrealized gain (loss) which was included in other comprehensive income (a separate component of shareholders' equity) for available-for-sale securities transferred to trading securities during the period. Additionally, this item would include any gains (losses) realized during the period from the sale of investments accounted for under the cost method of accounting and losses recognized for other than temporary impairments (OTTI) of the subject investments.

+ References+ Details

Variable Interest Entity - Additional Information (Detail) (USD $)	1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended	20 Months Ended
	Sep. 30, 2014	Feb. 29, 2012 Soybean_Grower	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Aug. 31, 2014
Variable Interest Entity [Line Items]
Aggregate value of common stock purchased						$ 1,450,000
Research and development expenses			3,179,000	3,684,000	7,097,000	7,942,000
Bioceres, S.A. [Member]
Variable Interest Entity [Line Items]
Number of soybean growers owned		230
Variable interest entity agreement, terms					Both the Company and Bioceres, Inc. incur expenses in support of specific agreed activities on behalf of Verdeca, as defined by joint work plans, which apply fair market value to each partner’s activities. Verdeca is not the primary obligor for these activities performed by the Company or Bioceres, Inc. Unequal contributions of services are equalized by the partners through cash payments. An agreement executed in conjunction with the formation of Verdeca specifies that if Bioceres Inc. determines it requires cash to fund its contributed services (subject to certain annual limits), Bioceres, S.A. may elect to sell shares of its common stock to the Company for an amount not exceeding $5.0 million in the aggregate over a four-year period.
Funding period of cash required for contributed services					4 years
Aggregate value of common stock purchased								2,000,000
Reduction in commitments to purchase stock	500,000
Number of shares surrendered	1,832
Research and development expenses							1,500,000
Direct and allocated overhead amount			900,000	200,000	1,200,000	700,000
Bioceres, S.A. [Member] \| Research Services Expenses, Soybean Events [Member]
Variable Interest Entity [Line Items]
Subcontracted services					700,000
Bioceres, S.A. [Member] \| Maximum [Member]
Variable Interest Entity [Line Items]
Cash required for funding its contributed services					5,000,000
Commitment to purchase stock					$ 1,200,000		$ 2,000,000

Debt - Summary of Long-Term Debt (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2015	Dec. 31, 2014
Debt Disclosure [Abstract]
Notes payable	$ 19,462
Note payable to related party		8,000
Promissory note		1,924
Total	19,462	9,924
Less current portion		(1,055)
Long-term portion	$ 19,462	$ 8,869

Debt - Long-term Debt - Additional Information (Detail) (USD $)	9 Months Ended					1 Months Ended	3 Months Ended	9 Months Ended	1 Months Ended		9 Months Ended	1 Months Ended	9 Months Ended		1 Months Ended			9 Months Ended		1 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Nov. 30, 2013	Aug. 31, 2013	Apr. 30, 2015 Loans Payable [Member] Term Note [Member]	Sep. 30, 2015 Loans Payable [Member] Term Note [Member]	Sep. 30, 2015 Loans Payable [Member] Term Note [Member]	Apr. 30, 2015 Loans Payable [Member] Term Note [Member] Three-month LIBOR [Member]	Apr. 30, 2015 Loans Payable [Member] Minimum [Member] Term Note [Member]	Sep. 30, 2015 Loans Payable [Member] Minimum [Member] Term Note [Member]	Apr. 30, 2015 Notes Payable Other Payables [Member] Promissory Notes [Member]	Sep. 30, 2015 Notes Payable Other Payables [Member] Promissory Notes [Member]	Jul. 31, 2012 Moral Compass Corporation [Member]	Jul. 31, 2012 Moral Compass Corporation [Member] Term Note [Member]	Dec. 31, 2014 Moral Compass Corporation [Member] Term Note [Member]	Nov. 10, 2014 Moral Compass Corporation [Member] Term Note [Member]	Sep. 30, 2015 Moral Compass Corporation [Member] Amended Note [Member]	Sep. 30, 2015 Moral Compass Corporation [Member] Minimum [Member] Term Note [Member]	Apr. 30, 2015 Moral Compass Corporation [Member] Loans Payable [Member] Term Note [Member]
Debt Instrument [Line Items]
Note payable			$ 8,000,000											$ 8,000,000	$ 8,000,000	$ 8,000,000	$ 8,000,000
Debt instrument term													36 months		36 months
Interest rate spread on loan									8.74%	9.00%					2.00%			11.00%		2.00%
Debt instruments maturity month year															2015-07
Maturity date description																		(i) April 1, 2016, (ii) the date of an Event of Default, or (iii) a date designated by MCC, by notice to the Company, no earlier than the 20th day following consummation by the Company of an equity financing with gross proceeds to the Company of at least $50 million.
Gross proceeds from equity financing																			50,000,000
Accrued interest due to related parties																36,000
Repayment of principal balance												1,600,000								8,000,000
Repayment of accrued interest and prepayment fee												44,000								100,000
Notes payable to unrelated party			869,000	1,100,000	2,000,000
Interest rate on loan													10.00%
Term Loans principal amount						20,000,000
Interest rate terms description								Under this loan agreement, interest on the Term Loans accrues at a rate per annum equal to the greater of (i) 9.0% and (ii) a fluctuating rate of interest equal to three-month LIBOR as in effect from time to time plus 8.74%.
Repayment date of outstanding principal amounts and accrued interest								Nov. 01, 2018
Additional term payment due on maturity of term loan						600,000
Debt instrument, covenant compliance description								The loan and security agreement includes customary covenants for credit facilities of this type. In addition, the agreement contains a financial covenant with respect to quarterly revenue targets, which shall not be less than 80% of the projected revenue for such periods, or cash and cash equivalents on hand which shall be at least 50% of the outstanding loan amount. As of September 30, 2015, the Company is in compliance with such covenants. The obligations under the loan agreement are secured by substantially all of the Company’s assets.
Debt instrument, violation or event of default description								In July 2015, the Company amended the loan agreement to include certain intellectual property rights in exchange for a waiver of the Company’s obligation to obtain a subordination agreement from Mahyco International Pte, Ltd. (“Mahyco International”) with respect to the indebtedness the Company owes to Mahyco International. If any of these events of default occurs, the lenders may accelerate and declare to be immediately due and payable the outstanding principal amount of the Term Loans and the Company’s other payment obligations under the agreement. In the case of a bankruptcy or insolvency event of default, the outstanding principal amount of the Term Loans and the Company’s other payment obligations under the loan agreement automatically are accelerated and become due and payable. In addition, if an event of default occurs and is continuing under the loan agreement, the lenders may exercise certain additional secured creditor remedies against the Company and against the assets securing the Company’s obligations under the agreement.
Percentage of quarterly revenue target projected											80.00%
Percentage of cash and cash equivalents on outstanding loan amount											50.00%
Common stock warrants issued						1,503,760
Common stock warrants, exercise price per share						$ 5.32
Warrant liability, fair value						400,000
Embedded derivative liability, fair value						81,000
Fees paid to lender	290,000							300,000
Interest expense related to debt discount	589,000	342,000					100,000	200,000
IPO completion date								2015-05
Initial fair value of warrants and embedded derivative liability							400,000	400,000
Interest expense related to combined term loans							$ 600,000	$ 1,000,000

Debt - Convertible Promissory Notes - Additional Information (Detail) (USD $)	9 Months Ended						1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Sep. 30, 2015 Binomial lattice option-pricing method [Member]	Sep. 30, 2015 Monte Carlo simulation method [Member]	Sep. 30, 2013 Mahyo Convertible Promissory Notes [Member] Medium-term Notes [Member]	Sep. 30, 2015 Mahyo Convertible Promissory Notes [Member] Long-term Debt [Member] Common stock warrant [Member]	Sep. 30, 2014 Mahyo Convertible Promissory Notes [Member] Long-term Debt [Member] Common stock warrant [Member]	Sep. 30, 2015 Mahyo Convertible Promissory Notes [Member] Long-term Debt [Member] Common stock warrant [Member]	Sep. 30, 2014 Mahyo Convertible Promissory Notes [Member] Long-term Debt [Member] Common stock warrant [Member]	Sep. 30, 2015 Mahyo Convertible Promissory Notes [Member] Long-term Debt [Member] Binomial lattice option-pricing method [Member]
Debt Instrument [Line Items]
Additional convertible promissory notes			$ 4,500,000	$ 500,000		$ 5,000,000
Interest on the notes							2.00%
Conversion price							$ 16.52
Percentage of price per share of recent offering for conversion price per share of notes outstanding							90.00%
Convertible debt					5,000,000
Debt instrument term												5 years
Number of warrant to purchase common stock issued								75,666		75,666
Warrant, exercise price								$ 16.52		$ 16.52
Warrant, vesting date										2013-12
Warrant, exercisable term										5 years
Interest expense related to convertible promissory note								200,000	200,000	600,000	700,000
Interest expense related to debt discount	589,000	342,000						100,000	200,000	400,000	500,000
Increase in fair value of warrant	$ 200,000

Stock-Based Compensation - Additional Information (Detail) (USD $) In Millions, except Share data, unless otherwise specified	9 Months Ended			9 Months Ended		0 Months Ended	9 Months Ended	0 Months Ended				0 Months Ended	9 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2015 IncentivePlan	Sep. 30, 2015 Employee Stock Option [Member]	Dec. 31, 2014 Employee Stock Option [Member]	Sep. 30, 2015 Minimum [Member]	Sep. 30, 2015 Maximum [Member]	May 20, 2015 2015 Omnibus Equity Incentive Plan [Member]	Sep. 30, 2015 2015 Omnibus Equity Incentive Plan [Member]	May 20, 2015 2015 Omnibus Equity Incentive Plan [Member] Share-based Compensation Award, Tranche One [Member]	May 20, 2015 2015 Omnibus Equity Incentive Plan [Member] Maximum [Member]	Sep. 30, 2015 2006 Stock Incentive Plan [Member]	May 20, 2015 2006 Stock Incentive Plan [Member]	May 14, 2015 2015 Employee Stock Purchase Plan [Member]	Sep. 30, 2015 2015 Employee Stock Purchase Plan [Member]	Sep. 30, 2015 2015 Employee Stock Purchase Plan [Member] Employee Stock Option [Member]	Sep. 30, 2014 2015 Employee Stock Purchase Plan [Member] Employee Stock Option [Member]	Sep. 30, 2015 2015 Employee Stock Purchase Plan [Member] Employee Stock Option [Member]	Sep. 30, 2014 2015 Employee Stock Purchase Plan [Member] Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity incentive plans	2
Options vesting period				2 years 3 months	4 years	4 years
Terms under the plan							The 2015 Plan became effective upon the IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 3,087,729 shares of common stock reserved for future issuance, which included 212,729 shares under the 2006 Plan that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant, beginning on January 1, 2016. In addition, shares subject to awards under the 2006 Plan that are forfeited or terminated will be added to the 2015 Plan. The 2015 Plan provides for the grant of incentive stock options (“ISOs”), nonstatutory stock options (“NSOs”), restricted stock awards, stock units, stock appreciation rights, and other forms of equity compensation, all of which may be granted to employees, officers, non-employee directors, and consultants.
Total number of shares reserved for issuance under plan						3,087,729	3,089,340				212,729
Stock options vesting percentage at end of one year								25.00%
Options exercisable period									10 years
Common stock available for future grant							3,044,340
Number of options granted under director compensation plan		352,493					45,000							0	0		0
Total number of options outstanding		3,744,534	3,759,839				45,000			3,699,534
Unrecognized compensation cost related to unvested stock-based compensation grants													$ 1.4
Weighted-average remaining recognition period													2 years 3 months 18 days
Estimated grant-date fair value of employee stock options granted														$ 0		$ 4.61
Percentage in payroll deductions to acquire shares of common stock												15.00%
Purchase plan offering period												6 months
Employees are able to purchase company's common stock on first trading day of offering period, percentage												85.00%
Common stock reserved for issuance under employee stock purchase plan												625,000
Issuance of common stock pursuant to employee stock purchase plan													0
First offering period, start date													May 14, 2015
First offering period, end date													Feb. 01, 2016

Stock-Based Compensation - Summary of Activity Under Stock Incentive Plans (Detail) (Employee Stock Option [Member], USD $) In Thousands, except Share data, unless otherwise specified	9 Months Ended
	Sep. 30, 2015
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Subject to Outstanding Options, Beginning Balance	3,759,839
Shares Subject to Outstanding Options, Options granted	352,493
Shares Subject to Outstanding Options, Options exercised	(355,965)
Shares Subject to Outstanding Options, Options cancelled and forfeited	(11,833)
Shares Subject to Outstanding Options, Ending Balance	3,744,534
Shares Subject to Outstanding Options, Options vested and exercisable	3,359,944
Weighted-Average Exercise Price Per Share, Beginning Balance	$ 3.00
Weighted-Average Exercise Price Per Share, Options granted	$ 7.30
Weighted-Average Exercise Price Per Share, Options exercised	$ 0.53
Weighted-Average Exercise Price Per Share, Options cancelled and forfeited	$ 7.92
Weighted-Average Exercise Price Per Share, Ending Balance	$ 3.61
Weighted-Average Exercise Price Per Share, Options vested and exercisable	$ 3.20
Aggregate Intrinsic Value, Outstanding at beginning balance	$ 12,499
Aggregate Intrinsic Value, Outstanding at ending balance	4,332
Aggregate Intrinsic Value, Options vested and exercisable	$ 4,322

Income Taxes - Additional Information (Detail)	3 Months Ended		9 Months Ended
Income Taxes - Additional Information (Detail)	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Tax Disclosure [Abstract]
Expected income tax provision at the federal statutory rate			34.00%
Effective tax rate (ETR)	2.10%	(0.60%)	(1.60%)	(1.50%)

Net Loss per Share - Schedule of Securities Not Included in Diluted Per Share Calculations (Detail)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	5,401,892	38,256,766
Option to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	3,744,534	3,642,971
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount		23,385,029
Redeemable Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount		9,587,764
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	1,336,894	1,336,894
Convertible Promissory Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	320,464	304,108

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References+ Details

Related-Party Transactions - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended						3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Jul. 31, 2012 Moral Compass Corporation [Member]	Sep. 30, 2015 Blue Horse Labs Inc [Member]	Dec. 31, 2014 Blue Horse Labs Inc [Member]	Sep. 30, 2015 Limagrain Cereal Seeds LLC [Member]	Sep. 30, 2014 Limagrain Cereal Seeds LLC [Member]	Sep. 30, 2015 Limagrain Cereal Seeds LLC [Member]	Sep. 30, 2014 Limagrain Cereal Seeds LLC [Member]	Dec. 31, 2014 Limagrain Cereal Seeds LLC [Member]
Related Party Transaction [Line Items]
Note payable					$ 8,000,000	$ 8,000,000
Royalty fees due	15,000		15,000		56,000		15,000	21,000
Revenue recognized	23,000	23,000	68,000	68,000					23,000	23,000	68,000	68,000
Amounts due from Limagrain									$ 0		$ 0		$ 0

- Definition

For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.

+ References+ Details